Ocular Therapeutix Inc. (OCUL)
NASDAQ: OCUL
· Real-Time Price · USD
8.02
-0.12 (-1.47%)
At close: May 30, 2025, 3:59 PM
8.01
-0.06%
After-hours: May 30, 2025, 04:47 PM EDT
-1.47% (1D)
| Bid | 7.74 |
| Market Cap | 1.28B |
| Revenue (ttm) | 59.58M |
| Net Income (ttm) | -192.71M |
| EPS (ttm) | -1.15 |
| PE Ratio (ttm) | -6.97 |
| Forward PE | -5.52 |
| Analyst | Buy |
| Ask | 8.25 |
| Volume | 1,726,585 |
| Avg. Volume (20D) | 1,776,869 |
| Open | 8.08 |
| Previous Close | 8.14 |
| Day's Range | 7.72 - 8.15 |
| 52-Week Range | 4.79 - 11.78 |
| Beta | 1.50 |
About OCUL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OCUL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for OCUL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
+13.69%
Ocular Therapeutix shares are trading higher after...
Unlock content with
Pro Subscription
3 weeks ago
-12.16%
Ocular Therapeutix shares are trading lower after the company reported worse-than-expected Q1 financial results.
2 months ago · seekingalpha.com
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster PotentialOcular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has ...
